Sean Laaman
Stock Analyst at Morgan Stanley
(2.69)
# 2,141
Out of 5,032 analysts
10
Total ratings
77.78%
Success rate
12.17%
Average return
Main Sectors:
Stocks Rated by Sean Laaman
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| EXEL Exelixis | Maintains: Overweight | $46 → $50 | $34.09 | +46.67% | 2 | Sep 17, 2025 | |
| IRON Disc Medicine | Maintains: Overweight | $85 → $90 | $87.74 | +2.58% | 2 | Aug 18, 2025 | |
| AXSM Axsome Therapeutics | Assumes: Overweight | $190 | $130.00 | +46.15% | 1 | Jul 3, 2025 | |
| CERT Certara | Assumes: Equal-Weight | $16 | $12.26 | +30.51% | 1 | Jul 3, 2025 | |
| ONC BeOne Medicines AG | Maintains: Overweight | $313 → $330 | $319.68 | +3.23% | 1 | Jun 27, 2025 | |
| ALEC Alector | Assumes: Underweight | $3 → $1.5 | $3.15 | -52.31% | 1 | Mar 7, 2025 | |
| HALO Halozyme Therapeutics | Assumes: Overweight | $67 | $66.33 | +1.01% | 1 | Feb 14, 2025 | |
| RMD ResMed | Upgrades: Overweight | $169 | $269.70 | -37.34% | 1 | Oct 27, 2023 |
Exelixis
Sep 17, 2025
Maintains: Overweight
Price Target: $46 → $50
Current: $34.09
Upside: +46.67%
Disc Medicine
Aug 18, 2025
Maintains: Overweight
Price Target: $85 → $90
Current: $87.74
Upside: +2.58%
Axsome Therapeutics
Jul 3, 2025
Assumes: Overweight
Price Target: $190
Current: $130.00
Upside: +46.15%
Certara
Jul 3, 2025
Assumes: Equal-Weight
Price Target: $16
Current: $12.26
Upside: +30.51%
BeOne Medicines AG
Jun 27, 2025
Maintains: Overweight
Price Target: $313 → $330
Current: $319.68
Upside: +3.23%
Alector
Mar 7, 2025
Assumes: Underweight
Price Target: $3 → $1.5
Current: $3.15
Upside: -52.31%
Halozyme Therapeutics
Feb 14, 2025
Assumes: Overweight
Price Target: $67
Current: $66.33
Upside: +1.01%
ResMed
Oct 27, 2023
Upgrades: Overweight
Price Target: $169
Current: $269.70
Upside: -37.34%